---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-21-015854"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2021-08-05T23:59:59+00:00"
generated_at: "2026-06-29T21:42:46.606295+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aurinia Q2 2021 revenue $6.6M, 415 LUPKYNIS PSFs, guides FY revenue $40-50M

## Summary
- Net revenue $6.6M (624% growth over Q1 2021); net loss $47.0M ($0.37/share) vs $26.5M loss in Q2 2020.
- Received 415 LUPKYNIS patient start forms in Q2, over 800 YTD; >50% converted to therapy.
- Cash and investments $323.7M; 2021 LUPKYNIS net revenue guidance $40-50M.
- Otsuka filed MAA in EU for voclosporin; Aurinia eligible for up to $30M milestones plus royalties.
- Appointed Dr. Brinda Balakrishnan to Board; Lancet published AURORA-1 results.

## SEC filing metadata
- accession: 0001628280-21-015854
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2021-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000162828021015854/0001628280-21-015854-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000162828021015854/auph-20210805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-21-015854
- JSON: https://secwatch.observer/filing/0001628280-21-015854.json
- Plain text: https://secwatch.observer/filing/0001628280-21-015854.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.